More Companies Apply For Additional Indication Of Gemzar
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku and Hospira Japan announced they both have filed applications for additional indications for the generic anti-cancer drug gemcitabine for treatment of relapsed or refractory malignant lymphoma.